Summary of Kelun Biotech Conference Call Company Overview - **Company**: Kelun Biotech (6990.HK) - **Industry**: Biotechnology, specifically focusing on antibody-drug conjugates (ADCs) Key Points 1. Strong Sales Growth - Significant sales ramp-up for sac-TMT (TROP2 ADC) observed in Q2, primarily driven by 3L EGFRmut NSCLC following NMPA approval in March - First commercial interim results reported at Rmb302 million for sac-TMT, on track to meet FY25 guidance of Rmb800 million to Rmb1 billion - Achieved commercial profitability in H1 2025, with drug sales surpassing SG&A expenses, and expects firmwide profitability in the near term due to licensing income from MSD partnership, estimated at US$100 million to US$150 million per year [3][4][8] 2. Upcoming Data Presentation at ESMO 2025 - ESMO 2025 (October 17-21) is anticipated to be a data-rich event for Kelun Biotech - Management highlighted three LBA presentations, including: - Clinical readouts from Phase 3 studies of sac-TMT in 2L EGFRmut NSCLC and HR+/HER2- breast cancer - Phase 3 head-to-head study of A166 (HER2 ADC) versus T-DM1 - POC-stage data for various tumor types, including ph2 ORR data of sac-TMT combined with Keytruda in 1L PD-L1+ NSCLC [4][7] 3. Early Pipeline Developments - Kelun Biotech is progressing its early-stage ADC pipeline, including: - SKB410 (Nectin-4 ADC, Phase 2 global study led by MSD) - SKB518 (PTK7 ADC, Phase 1b/2) showing early anti-tumor signals in NSCLC and SCLC - SKB571 (EGFR/c-Met ADC, Phase 1) undergoing dose-escalation trials - Management prefers to release data with certain maturity to provide a comprehensive drug profile [7][8] 4. Investment Rating and Price Target - Goldman Sachs maintains a Buy rating on Kelun Biotech with a 12-month price target of HK$454.04 - Current price is HK$491.40, indicating a downside potential of 7.6% - Key risks include R&D challenges, competition in the ADC field, limited commercial track record, talent competition, and partnership risks [8][9] 5. Financial Projections - Market cap: HK$114.6 billion (approximately US$14.7 billion) - Revenue projections for the next few years: - 2024: Rmb1,933 million - 2025E: Rmb1,950.6 million - 2026E: Rmb3,579.7 million - 2027E: Rmb5,432.9 million - EBITDA projections show a turnaround from negative to positive by 2026 [9] Additional Insights - The company is focusing on achieving greater visibility into the differentiated profiles and treatment potential of its next-generation assets through upcoming data releases [7] - The management's emphasis on commercial profitability and the strategic partnership with MSD indicates a strong outlook for future growth in the ADC market [3][4][8]

Summary of J.P. Morgan's China Healthcare Sector Conference Call Industry Overview - The conference call focused on the **China Healthcare sector**, particularly the **biotech** and **pharmaceutical** subsectors, which have shown significant financial performance in the first half of 2025 (1H25) [1][4]. Key Financial Performance - The **MSCI China Healthcare Index** and **Hang Seng Healthcare Index** have rallied over **70%** and **100%** respectively year-to-date [1]. - Most companies in the China healthcare sector met or slightly exceeded financial expectations for 1H25, with biotech companies showing solid growth in both top-line and bottom-line metrics [1][4]. Subsector Insights - **Biotech**: Remains a strong performer with robust growth driven by out-licensing, efficiency improvements, and cost control. Companies like **Kelun Biotech**, **RemeGen**, and **Innovent** reported results that met or exceeded expectations, prompting raised price targets [4][5]. - **CXO**: Continued positive momentum with companies like **WuXi AppTec**, **WuXi Bio**, and **WuXi XDC** exceeding market expectations and raising FY25 guidance [6]. - **Pharma**: Experienced slight revenue pressure, potentially due to **volume-based procurement (VBP)**, but net profit showed mild recovery year-over-year (YoY) and quarter-over-quarter (QoQ) [5]. - **Medtech**: Reported mixed results with some companies experiencing revenue growth while others faced declines. The competitive landscape is shifting, with **United Imaging** gaining market share [6]. - **Diagnostics**: Faced overall pressure with significant sales declines for key players due to price reductions and policy changes [12]. Market Dynamics and Future Outlook - The Hang Seng Healthcare Index saw a **10%** surge in the last 30 days, indicating a search for broader catalysts to sustain growth [4]. - Upcoming events such as **WCLC'25** and **ESMO'25** are expected to be significant catalysts for the sector [4]. - The sector is also looking forward to outcomes from **NRDL negotiations** and the drug coverage list from commercial health insurance in late 2025 [4]. Company-Specific Highlights - **Innovent** is highlighted as a top pick due to its diversified and innovative pipeline [4]. - **Akeso** showed potential despite results falling short of expectations, with promising data from its **HARMONi-A** trial [4]. - **Hengrui** is pursuing an independent global expansion strategy, which may lead to increased licensing income in the future [5]. Risks and Challenges - The **pharmacy sector** is expected to see consolidation, with an anticipated **100,000 store closures** in 2025 and 2026 [6]. - **Consumer sentiment** remains weak, impacting medical services and growth for companies like **Topchoice** and **Aier** [6]. Conclusion - The China healthcare sector is poised for further growth, driven by innovation and upcoming catalysts, despite facing challenges in certain subsectors. The overall sentiment remains optimistic, particularly for biotech and CXO companies, while pharma and diagnostics may require strategic adjustments to navigate current pressures [1][4][6].

Summary of Kelun Biotech Earnings Review Company Overview - **Company**: Kelun Biotech (6990.HK) - **Industry**: Biotech, specifically focused on developing and commercializing differentiated antibody drug conjugates (ADCs) for global patients [8][9] Key Financial Highlights - **1H Revenue**: Rmb950 million, with Rmb302 million from sac-TMT and Rmb628 million from licensing income, both broadly in-line with expectations [1] - **Net Loss**: Rmb-145 million, narrower than the expected Rmb-184 million, attributed to managed SG&A spending of Rmb253 million, which increased by 6% half-on-half [1] - **Cash Position**: Rmb4.5 billion in cash equivalents, up from Rmb3.1 billion by year-end 2024, sufficient to support near-term operations [1] Product Performance and Outlook - **sac-TMT**: Achieved high double-digit month-over-month growth, with NSCLC patients becoming the majority post-March approval. Management is confident in accelerated growth in the second half of the year [2][6] - **Mature Products**: Limited revenue in 1H, but expected growth post-NRDL coverage beyond 2025 [2] - **Next Potential Asset**: SKB571 (EGFR/cMET BsADC) is being positioned as the next anchor asset, with ongoing Phase 2 trials [6] Research and Development Insights - **R&D Expenses**: Decreased to Rmb612 million in 1H25, down 6% year-on-year, as more late-stage assets enter NDA or later stages [1] - **Pipeline Development**: Focus on addressing unmet medical needs with a variety of drug candidates in early-stage development [6] Valuation and Price Target - **Target Price Adjustment**: 12-month target price adjusted to HK$454.04 from HK$406.74, based on risk-adjusted DCF methodology [7] - **Earnings Per Share (EPS) Estimates**: Adjusted for 2025E-27E to reflect updated financials and lowered sales estimates for certain products [7] Risks and Challenges - **Key Risks**: Include R&D risks in developing new indications, competition in the ADC field, limited commercial manufacturing and sales track record, talent competition, and alliance risks [8][10] Conclusion - **Investment Rating**: The company is rated as a Buy, with expectations for meaningful growth driven by its product pipeline and strategic collaborations [9][11]

Investment Rating - The report suggests an "Overweight" rating for sectors benefiting from the influx of educated youth into the workforce, particularly in services, healthcare, financial services, high-tech industries, and hospitality & entertainment [66][69]. Core Insights - Youth unemployment in China has increased significantly, from approximately 10% in 2018 to around 21% in the summer of 2023, but this is viewed as an opportunity rather than a threat due to the unprecedented level of education among the youth entering the workforce [2][5][6]. - China is transitioning from an industrial policy-driven economy to a services-oriented economy, with a notable increase in the contribution of services to GDP, which has risen from 32% in 1990 to 55% in 2023 [4][53]. - The report highlights that the most educated cohort in China's history is entering the labor market, with tertiary education enrollment rates soaring from 3% in 1990 to 75% in 2023, indicating a well-prepared workforce [4][14][10]. Summary by Sections Youth Unemployment - Youth unemployment is currently misinterpreted as a threat, while it actually presents an opportunity for economic growth as the most educated population enters the workforce [6][13]. - The report emphasizes that the rise in youth unemployment should be viewed through the lens of potential service consumption growth [6][20]. Human Capital Development - China has rapidly upskilled its population, with 15,467 per 100,000 now holding a degree, a fourfold increase over the past 20 years [4][10]. - Investment in education has increased from 2.4% of GDP in 2005 to 4.0% in 2022, leading to a significant rise in STEM graduates [4][39]. Service Sector Growth - The services sector in China is expected to grow significantly, with the potential to reach levels comparable to the US, where services contribute 76% to GDP [53][55]. - Key sectors identified for growth include healthcare, financial services, high-tech industries, and hospitality & entertainment, which currently employ a lower percentage of the labor force compared to the US [62][66]. Investment Opportunities - The report lists specific companies that are well-positioned to benefit from the growth in service consumption, including Trip.com, MGM China, NetEase, and Ping An Group, among others [66][69][88]. - The financial intermediation sector is highlighted as having substantial growth potential, particularly in health and protection products, with a noted lack of active CPAs in China compared to the US [70][69]. Healthcare Sector - The healthcare sector is poised for growth, with China now holding a 20% share of global PCT patent publications in biotechnology, second only to the US [76][81]. - The report identifies companies like Innovent and Akeso as potential beneficiaries of the expanding healthcare services market [76][81].

Investment Rating - The report indicates a positive outlook for the China healthcare sector, with a recovery underway and improving investor sentiment, particularly in the biotech segment, which has seen a year-to-date performance increase of 37% [1]. Core Insights - The report highlights a significant recovery in the China healthcare sector, driven by improving investor sentiment and bottoming valuations, with offshore healthcare stocks up 21% year-to-date [1]. - Biotech companies are expected to benefit from licensing-out themes and resilience to geopolitical uncertainties, with key events like ASCO in June serving as potential catalysts for individual stock performance [1]. - There is a growing interest in domestic demand, particularly in capital expenditures and hospital traffic, with robust equipment tendering observed [1]. - The report anticipates a consumption recovery in areas such as refractive surgeries and orthodontics, although the sustainability of this recovery is contingent on the broader macroeconomic outlook [6]. - The report emphasizes the importance of global collaboration and licensing opportunities for pharmaceutical companies, with a focus on upcoming data releases at ASCO to enhance business development visibility [16]. Summary by Relevant Sections Biotech - The biotech sector is focusing on global licensing deals and achieving break-even points, with significant catalysts expected from the upcoming ASCO conference [13][14]. - Companies like Zai Lab and Innovent are highlighted for their innovative drug pipelines and potential for global collaboration [14][15]. Pharma - The pharmaceutical industry experienced soft growth in Q1 2025, but companies with strong product cycles, such as Hengrui, are showing better earnings trends [16]. - Collaboration opportunities are expected to increase, particularly with data releases at ASCO [16]. CDMO - CDMO companies reported better-than-expected results in Q1 2025, with strong order growth and maintained guidance for FY25 [17]. - Companies like WuXi Apptec and Asymchem are noted for their resilience in earnings delivery [17]. Medical Consumables - The report indicates challenges in inpatient surgeries due to reimbursement controls, but opportunities exist in the obesity and GLP-1 segments [19]. - Surgical volumes are expected to remain challenging, with ongoing pricing pressures [19]. Capital Equipment - Strong tendering activity was noted, but pricing pressures from value-based purchasing (VBP) are leading to longer revenue realization timelines [21]. - Companies like United Imaging and Mindray are expected to see positive growth in the coming quarters [21]. Retail Pharmacy - The retail pharmacy sector is undergoing a market clearing process, with a net decrease in drugstores for the first time, indicating a consolidation trend [26]. - Yifeng is highlighted as a resilient player in this space, benefiting from operational efficiency [26].

Investment Rating - The report assigns an "Overweight" (OW) rating to Innovent, Akeso, and Kelun Biotech, indicating an expectation that these stocks will outperform the average total return of their coverage universe [4][7]. Core Insights - Innovent has shown strong investor interest, with a recent stock increase of approximately 3% following a share sale by Lilly Asia Ventures. The company achieved its first-ever non-IFRS positive profit and EBITDA in 2024, and this trend is expected to continue into 2025 and beyond. Innovent is anticipated to secure an outlicensing deal for IBI363, which holds significant value in the immuno-oncology therapy space [4]. - Akeso's share price rose by 10% on June 10, attributed to comments from its U.S. partner, Summit, regarding avoiding a cash raise and manufacturing Ivonescimab in-house. Summit plans to recruit participants for global trials from multiple regions, including China, the U.S., and the EU. The BLA filing strategy for HARMONi is still under discussion [4]. - Kelun Biotech completed an equity raise and does not require additional cash due to solid reserves. Promising ASCO data for Sac-TMT in treating triple-negative breast cancer and non-squamous non-small cell lung cancer indicates a higher probability of success in Phase 3 trials. The domestic Phase 3 trial is enrolling patients rapidly, with potential for an interim analysis this year [4][5]. Summary by Company Innovent - Innovent's stock increased by ~3% after a secondary share placement by Lilly Asia Ventures, which still holds a ~2% stake. The company achieved its first non-IFRS positive profit and EBITDA in 2024, with expectations for continued growth in 2025. Anticipated catalysts include an outlicensing deal for IBI363 [4][5]. Akeso - Akeso's share price increased by 10% following positive comments from Summit, its U.S. partner. Summit is working on in-house manufacturing of Ivonescimab and plans to recruit trial participants from various regions. The BLA filing strategy for HARMONi is still being evaluated [4][5]. Kelun Biotech - Kelun Biotech completed an equity raise and has solid cash reserves. Promising data for Sac-TMT in treating specific cancers suggests a high probability of success in upcoming trials. The company is rapidly enrolling patients for a domestic Phase 3 trial, with potential for an interim analysis this year [4][5].

Investment Rating - The report maintains a "Buy" rating for several healthcare stocks, including Wuxi Apptec and Eyebright, based on their strong growth potential and market positioning [11]. Core Insights - The EU's planned restrictions on Chinese medtech firms' access to public procurements over EUR 5 million are expected to have limited impact on the covered companies, as most do not participate in such procurements and have manageable revenue exposure to the EU market [3]. - The healthcare indices in China showed positive performance, with HSHCI rising by 4.1% and HSHKBIO by 4.5% during the week of June 2-6, 2025, indicating a favorable market trend [2]. - Recent approvals in the drug sector include Akeso's cadonilimab for cervical cancer and Hansoh's aumolertinib for NSCLC in the UK, showcasing ongoing innovation and regulatory progress in the industry [4][5]. Summary by Sections Market Access and Regulatory Environment - The EU's International Procurement Instrument investigation concluded that China has limited EU medical device producers' access to government contracts, leading to the proposed restrictions [3]. - Companies like Mindray and MGI Tech have established local manufacturing facilities, which may help mitigate the impact of these restrictions [3]. Drug Approvals and Developments - Akeso's cadonilimab received approval for treating first-line cervical cancer, while Innovent and Hutchmed's sintilimab + fruquintinib application was accepted for renal cell carcinoma [4]. - Hansoh's aumolertinib has been approved in the UK for specific NSCLC patients, indicating a strong pipeline for innovative therapies [4]. Stock Performance and Recommendations - The report highlights top picks in the healthcare sector, including Wuxi Apptec and Eyebright, based on their expected solid fundamental recovery and market share potential [11]. - The report notes that the chemicals sector outperformed healthcare indices, with a 1.7% increase in A shares and a 3.8% increase in H shares [12].

Investment Rating - The report does not explicitly provide an investment rating for the China drug industry but discusses potential impacts of US drug pricing changes on the sector [5]. Core Insights - The report highlights significant uncertainty regarding the Trump administration's plans for US drug pricing, which could affect the Chinese drug industry in various ways [5]. - Changes in US drug pricing could hinder the Chinese drug industry's international expansion due to a perceived smaller US market, but may also create opportunities for Chinese innovative drugs to be licensed out due to R&D cost advantages [5]. - The report notes that Chinese CRO/CDMO companies may face mixed impacts; reduced R&D expenses from US clients could negatively affect them, while increased outsourcing demand could arise as companies seek cost-saving measures [5]. Summary by Sections Impact of US Drug Pricing Changes - The report discusses the uncertainty surrounding the implementation of a "most favored nation" pricing model and its potential opposition in the US [5]. - It emphasizes that the actual impact on the Chinese drug industry remains unclear due to various factors, including whether Medicare or Medicaid pricing will be affected [5]. Opportunities and Challenges for Chinese Companies - If US drug prices decrease, it could limit the Chinese drug industry's ability to expand internationally [5]. - Conversely, innovative drugs from China may have better licensing opportunities due to their potential R&D cost and speed advantages [5]. - For Chinese CRO/CDMO companies, the report suggests that while some clients may cut R&D expenses, the overall demand for outsourcing could increase [5].

Summary of Key Points from the Conference Call on China Healthcare Equities Industry Overview - The conference focused on the **China Healthcare sector**, particularly the impact of US tariffs on the pharmaceutical supply chain and related industries [2][21]. Core Insights - **Tariff Impact Ranking**: The impact of tariffs is expected to be highest on medical consumables, followed by devices and drugs [2]. - **Timeline for Tariffs**: Tariffs on US pharmaceutical imports may commence within one to two months due to ongoing investigations [2]. - **Impact on Exporters**: Small and medium-sized exporters of low-end medical consumables are anticipated to be most affected, with major CDMOs like Wuxi AppTec, Pharmaron, and Genscript facing 30-50% revenue exposure to the US [2][21]. - **Risk Management**: Large companies are managing risks through planned production capacity shifts to ASEAN/Europe and maintaining high inventory levels (two to three years) [2]. - **API Exporters**: The risk for API exporters is considered manageable in the short term due to China's established supply chain role, despite having double-digit US revenue exposure [2]. Financial Projections - **Revenue and Profit Margin Erosion**: Scenario analysis indicates potential revenue and net profit margin erosion of approximately 5% and 1 percentage point across sub-sectors due to tariffs [3]. - **CDMO Impact**: CDMOs could see up to a 6% revenue impact and a 5-10% decrease in net profit margins [3]. - **Cost Inflation**: Import-dependent segments, such as IVD reagents, may experience around 1% cost inflation, slightly squeezing margins [3]. Market Dynamics - **Global Supply Chain Shifts**: The global supply chain is shifting, but short-term offsets are expected due to stockpiling [2]. - **Domestic Substitution**: There is an expectation of accelerating domestic substitution in the MedTech sector due to import weaknesses caused by tariffs [9]. - **Market Concentration**: A higher level of market concentration is anticipated in the MedTech subsector [9]. Company-Specific Insights - **Limited US Exposure**: Chinese innovative drugs are forecasted to have almost no sales exposure to the US, with limited impact from R&D cost increases due to higher export prices [7]. - **CDMO Resilience**: CDMOs are expected to manage tariff impacts effectively, with 80% of tariff expenses potentially passed through to US clients [8]. - **MedTech Companies**: Companies like Mindray and United Imaging are expected to face low single-digit cost impacts due to their low US exposure [9]. Export Data - **China Healthcare Exports**: Total exports from the China Healthcare sector reached **USD 107.99 billion** in 2024, marking a **5.8% year-on-year increase** [15]. - **Export Composition**: APIs accounted for approximately **40%** of total exports, while IVDs made up **21%** [15][18]. Conclusion - The China Healthcare sector is navigating potential tariff impacts with strategic adjustments and risk management practices. While certain sub-sectors may face challenges, the overall resilience of the industry, particularly in API production and innovative drug development, is expected to mitigate significant adverse effects.